BioSpace News Archive

EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, reports the completion of patient recruitment in the Phase II ACESO trial.

Sinovac Biotech Ltd. announced that its Board of Directors unanimously determined that the partial tender offer by Alternative Liquidity Index LP to acquire up to 10,000,000 common shares of Sinovac for $0.03 per share in cash is NOT advisable and is NOT in the best interests of the Company or its shareholders.

Baird Medical Investment Holdings Limited announced that its subsidiary, Nanjing Changcheng Medical Equipment Co., Ltd., has received approval of its Single-Use Sterile Biopsy Needle from Jiangsu Medical Products Administration, the drug regulatory body for Jiangsu Province in China.

NUCLIDIUM announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours, neuroendocrine tumours and prostate cancer at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine, 09-13 September 2023.

Aesthetic Medical International Holdings Group Limited, a leading provider of aesthetic medical services in China, announced its unaudited financial results for the six months ended June 30, 2023.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.

Vivani Medical, Inc. announced that its wholly-owned subsidiary Cortigent, Inc., a company pioneering targeted neurostimulation technology to recover critical body functions, will present the Early Feasibility Study results for the Orion® Visual Cortical Prosthesis System at The Eye & The Chip: 13th World Research Congress on Artificial Vision in Southfield, Michigan on October 8-10, 2023.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the full launch of Axoguard HA+ Nerve Protector.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced treatment of the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors.

Eledon Pharmaceuticals, Inc. announced the first participant has been dosed in the Company’s Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.